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tumour type, treatment methods used. Clinically signiﬁcant symptoms 
are found in 20-60% cancer patients. Lung cancer anaemia, deﬁnited as 
haemoglobin level below 12 g/dl is seen in 25-60% of patients depend-
ing on clinical stage (I-IV).
Materials and Methods: Between August 1997 and July 2000 in 
The Maria Sklodowska-Curie Memorial Cancer Centre and Institute, 
Department of Lung Cancer and Thoracic Tumours, 112 patients were 
treated by chemoradiotherapy with stage IIIA and IIIB non-small lung 
cancer. Thirty eight of patients were analyzed (31 males and 7 females). 
Median age was 57.8 (range 38-72). Current and never smokers consti-
tuted respectively 71% and 29% of patients.
Karnofsky status performance deﬁned as 100, 90, 80 was found in re-
spectively 36.8%, 47.4% and 15.8% of patients. Clinical stage IIIA and 
IIIB were diagnosed in 14 (36.8%) and 24 (63.2%) patients. Sequential 
treatment was given to 24 (63.2%) and concurrent chemoradiation 
was used in 14 (36.8%) patients. All patients received cisplatin and 
vinorelbine. All patients were irradiated to 60 Gy, using 3D planning 
system (Helax).
Results: Thirty six patients (94.7%) received planned treatment (2 
cycles of chemotherapy and irradiation). Only two patients (5.3%) 
had not completed treatment. Seventy eight chemotherapy cycles was 
given. Cisplatin total dose was between 130 to 360 mg per patient 
(median: 271 mg). Median treatment time was 46.1 days (range: 10-74 
days). Overall survival time in all patients was 98.3 weeks (range: 23-
389 weeks). Median time to progression was 34.6 weeks (range: 1-130 
weeks). Median haemoglobin serum level before treatment was 12.7 
g/dl (range: 10.2-16.0 g/dl). Median haemoglobin serum level after 
treatment was 12.4 g/dl (range: 7.7-16.1 g/dl). Median haemoglobin 
serum level one month after the end of treatment was 12.8 g/dl (range: 
8.1-15.3 g/dl).
Summary: Anaemia could be found as independent prognostic factor 
for overall survival time of lung cancer patients treated by combined 
radiochemotheraphy and it also may offer a predictive value. The corre-






Never smokers 11 29
KPS 100 14 36.8
KPS 90 18 47.4








CS IIIA 14 36.8
CS IIIB 24 63.2
RTCT concurrent 14 36.8
RTCT sequential 24 63.2
SCC 28 73.4
AC 1 2.6
NSCLC no subtype 9 23.7
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Background: NVB i.v. with CDDP has reported an optimal activity/
tolerance ratio when used in combination with radiotherapy (RT). The 
new oral formulation of NVB should be easier to use assuming a simi-
lar activity proﬁle. An international phase II trial with NVBo + CDDP 
as induction, followed by NVBo + CDDP + RT was implemented in 
order to evaluate the objective response (OR) following this combina-
tion by SWOG modiﬁed criteria and its safety (NCI-CTC v2).
Material and Methods: Patients (pts) between 18 and 70 years, with 
histologically proven untreated locally advanced inoperable stage 
IIIA/IIIB (supraclavicular lymph nodes and pleural effusion excluded) 
NSCLC, adequate bone marrow, hepatic and renal function, KPS ≥ 
80%, were treated with NVBo D1,8 60 mg/m2 cycle 1 and 80 mg/m2 
cycle 2 (if no grade 3-4 toxicity) and CDDP 80 mg/m2 every 3 weeks 
for 2 cycles as induction. Patients without progression received NVBo 
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D1,8 40 mg/m2 and CDDP 80 mg/m2 every 3 weeks for 2 more cycles 
and RT 66 Gy in 6.5 weeks. 
Results: Between 12/01 and 12/03, 54 pts were enrolled; stages IIIA 
48%, IIIB 52%; squamous 59%; median age 57 years (range 41-71), 
median KPS 100% (range 80-100%), 7% pts ≥ 5% weight loss at 
baseline. Relative dose intensities of NVBo/CDDP were 86%/93% and 
97%/98% at induction and in combination with RT, respectively. Forty-
one pts (76%) during induction increased NVBo from 60 to 80 mg/m2. 
Reasons for non-escalation: haematological 7 pts, non-haematological 
2, mistake 4. After 2 cycles of CT induction, OR (ITT) in the 54 pts 
was 37%. Toxicity during induction: G3-4 neutropenia (28%), febrile 
neutropenia (7%), G3 nausea (11%), G3-4 vomiting (9%), G3 anorexia 
(4%), G4 diarrhoea (2%), G3 constipation (2%). Forty-seven out of 
54 pts received CT-RT. Median RT delivered dose: 66 Gy. Tolerance: 
9% G3 neutropenia; no G3/4 oesophagitis; 2% G3 radiation dermatitis. 
Late pulmonary ﬁbrosis 1 pt. One month after CT-RT completion, OR 
(ITT) in the 54 pts was 54% (95%CI: 40%;67%). Median PFS/OS: 
12.5 (95%CI: 9.6;16.4) /23.4 (95%CI: 17.6;29.8) months, respectively.
Conclusion: NVB Oral with CDDP is effective in stage IIIA/IIIB pts. 
The excellent tolerance proﬁle allowed to complete the CT-RT treat-
ment in 94% of pts. NVB oral is a new and promising option which 
facilitates the concomitant administration of CT-RT.
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Background: SWOG 9504 demonstrated the beneﬁt of D consolida-
tion after E + C with radiation therapy in pts with locally advanced 
NSCLC. This study was developed to assess the feasibility and efﬁcacy 
of consolidation with either G alone or with D after the same chemora-
diation schedule as SWOG 9504.
Methods: The treatment schema included concurrent C 50 mg/m2 Day 
1, 8 + E 50 mg/m2 Day 1-5 for two 28-day cycles + RT 61-62 Gy over 
7 weeks, after which pts were randomized to consolidation treatment of 
either G 1000 mg/m2 Day 1, 8 (Arm A) or G 1000 mg/m2 Day 1, 8 + D 
75 mg/m2 Day 1 (Arm B) every 21 days for 3 cycles. Eighty-three pts 
were registered, and 58 were randomized to consolidation.
Results:
Characteristics/Results Induction Arm A Arm B
No. of available pts 83 32 32
Median age, yrs 59.0 59.5 59.5
Male 58 26 26
ECOG PS 0 32 11 13
ECOG PS 1 48 20 18
No. of pts assessed for safety, 
Consolidation  23 28
Neutropenia, Grade3/4, %  17.4 42.9
Febrile neutropenia, Grade 3/4, %  0 7.1
Thrombocytopenia, Grade 3/4, %  0 17.9
Anemia, Grade 3/4, %  0 7.1
Dyspnea, Grade 3/4, %  0 7.1
Pneumonitis, Grade 3/4, %  4.3 0
Fatigue, Grade3/4, %  4.3 17.9
Alopecia, Grade 2, %  4.3 3.6
Esophagitis, Grade 3/4, %  0 0
No. of cycles administered, %    
One  8.7 14.3
Two  4.3 25.0
Three  87.0 60.7
Response to chemoradiation    
No. assessed 83 29 29
CR, %  0 0
PR, % 44.6 55.2 62.1
SD, % 21.7 37.9 20.7
PD, % 3.6 0 0
Unknown, % 30.1 6.9 17.2
No. events for PFS  17 9
Median PFS, months  7.1 m 14.6 m
(95% CI)  (5.1, 10.7) (6.1, 24.3)
N for survival  32 32
Median follow-up for survival, 
months  15.5 m 11.2 m
No. events for survival  10 6
Median survival, months  18.5 NE
(95% CI)  (8.9, NE) (19.6, NE)
 
Conclusions: G or G+D following chemoradiation in locally advanced 
NSCLC is well tolerated. Preliminary data indicate that consolida-
tion with G+D resulted in a greater response rate and longer PFS. The 
doublet, as expected, resulted in more toxicity, particularly myelosup-
pression and fatigue.
